Asked by: Lord Wills (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what assessment they have made of the benefits to the NHS in England of early endovenous ablation of leg ulcers.
Answered by Lord O'Shaughnessy
The results of the Early Venous Reflux Ablation (EVRA) study (2018) and the Effect of Surgery and Compression on Healing and Recurrence (ESCHAR) trial (2004) indicate that early superficial endovenous ablation improves healing of venous leg ulceration, reduces the risk of ulcer recurrence and is cost-effective.
Therefore, the results of the EVRA study and the ESCHAR trial will be incorporated into the National Wound Care Strategy Programme recommendations for care, as this will bring benefits to both patients and the National Health Service.
Asked by: Lord Wills (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what assessment they have made of the efficacy of patient leg ulcer care pathways developed by the Venous Forum of the Royal Society of Medicine.
Answered by Lord O'Shaughnessy
NHS England is not aware of any assessments of the efficacy of patient leg ulcer care pathways developed by the Venous Forum of the Royal Society of Medicine.
There are plans to develop a national patient leg ulcer care pathway, and the Venous Forum has been invited to join the lower limb workstream to contribute to the development of this pathway.
Asked by: Lord Wills (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what assessment they have made of the benefits to people aged over 65 of endovenous ablation treatment of varicose veins.
Answered by Lord O'Shaughnessy
Varicose veins can cause complications because they stop blood flowing properly, including venous leg ulcers as a result of chronic venous insufficiency.
The results of the Early Venous Reflux Ablation (EVRA) study (2018) and the Effect of Surgery and Compression on Healing and Recurrence (ESCHAR) trial (2004) indicate that early superficial endovenous ablation improves healing of venous leg ulceration, reduces the risk of ulcer recurrence and is cost-effective.
Therefore, the results of the EVRA study and the ESCHAR trial will be incorporated into the National Wound Care Strategy Programme recommendations for care, as this will bring benefits to both patients and the National Health Service.
The EVRA study and the ESCHAR trial included patients over the age of 65 so the results are applicable to older people. However, no sub-analysis is presented for people over the age of 65 so it is not possible to identify if there are any benefits or risks beyond the overall results for people over 65.
Asked by: Lord Wills (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 5 April (HL6371), whether they have made any estimate of the cost of mesothelioma to the NHS; and if so, what.
Answered by Lord O'Shaughnessy
Neither the Department or its arm’s length bodies have made any formal assessment or estimate about the cost of mesothelioma to the National Health Service.
Asked by: Lord Wills (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 5 April (HL6371), whether anyone collects any data on the cost of mesothelioma to the NHS; and if so, who.
Answered by Lord O'Shaughnessy
While information is not held centrally, individual trusts may capture data relating to the cost of treating mesothelioma patients. However, this information could only be collected at disproportionate cost.
Asked by: Lord Wills (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 27 March, whether any data is collected on the cost of mesothelioma to the NHS; and if so, what.
Answered by Lord O'Shaughnessy
Data on the cost of mesothelioma to the National Health Service is not collected centrally.
Asked by: Lord Wills (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government what estimate they have made of the cost to the NHS of treating mesothelioma in each of the last 10 years.
Answered by Lord O'Shaughnessy
The information requested is not held national level.
Asked by: Lord Wills (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government what is the transfer of care rate for each local authority in England; and what assessment they have made of the reasons for any differences in the transfer of care rate between local authorities.
Answered by Lord Prior of Brampton
NHS England compiles and publishes monthly delayed transfers of care data. The data is available by each local authority and National Health Service trust, and includes the reason for the delay against a defined set of 10 categories. The data set is published in an online-only, interactive format.
Delays have multiple causes and as a result there is variation between local authorities. A wide-ranging package of support is in place to help areas improve transfers out of hospital and reduce delays, including work as part of Accident and Emergency Improvement Plans to understand and address delays in hospital discharge and promote good practice.
The NHS and local government have also developed new resources, including a high impact change model for reducing delayed transfers of care. In addition, the Emergency Care Improvement Programme provides tailored support to local systems to support rapid and sustained improvement in performance.